Please assess the completion status of the following clinical trial:

Trial Title: N-Acetylcysteine Augmentation in Treatment-Refractory Obsessive-Compulsive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* DSM-IV diagnosis of OCD, confirmed by SCID-IV; symptoms of at least 1 year duration~* moderate to severe OCD symptoms (Y-BOCS \> 16)~* documented failure of an adequate trial of an SSRI~* agreement to engage in a reliable form of birth control (women only)~Exclusion Criteria:~* primary diagnosis of a psychotic disorder~* active substance abuse or dependence~* unstable medical condition~* prior exposure to N-Acetylcysteine~* prior psychosurgery~* pregnancy, breastfeeding, or intent to become pregnant during study~* liver function tests (LFTs) elevated to more than 2x the upper limit of normal~* evidence of active liver disease~* seizure disorder~* active suicidal ideation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- N-Acetylcysteine (Type: EXPERIMENTAL): Patients randomized to this arm will receive N-Acetylcysteine augmentation, at a standard dose titrated to 3000 mg within the first week, in addition to the medication regimen they are on at enrollment
- placebo (Type: PLACEBO_COMPARATOR): Patients randomized to this arm will receive placebo, formulated to be indistinguishable from N-Acetylcysteine, in addition to the medication regimen they are on at study enrollment.

Based on this trial design, predict the completion outcome and termination type (if applicable).